Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
复制标题
DOI：
10.1016/s2213-8587(13)70208-0
复制
发表时间：
2014-05-01
影响因子：
44.5
通讯作者：
Broedl, Uli C.
中科院分区：
文献类型：
--
作者：
Barnett, Anthony H.;Mithal, Ambrish;Broedl, Uli C.
背景 糖尿病是全世界慢性肾病 (CKD) 的主要原因。 2 型糖尿病患者的最佳血糖控制对于最大限度地降低微血管和大血管并发症的风险并减缓 CKD 的进展非常重要。我们评估了恩格列净作为 2 型糖尿病合并 CKD 患者的辅助治疗的有效性和安全性。方法我们在 15 个国家的 127 个中心进行了一项 3 期、随机、双盲、平行组、安慰剂对照试验。 HbA(1c) 为 7% 或更高至 10% 或更低的患者有资格纳入。 2 期 CKD 患者（估计肾小球滤过率 [eGFR] >= 60 至 = 30 至
Background Diabetes is a leading cause of chronic kidney disease (CKD) worldwide. Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk of microvascular and macrovascular complications and to slow the progression of CKD. We assessed the efficacy and safety of empagliflozin as an add-on treatment in patients with type 2 diabetes and CKD.Methods We did a phase 3, randomised, double-blind, parallel-group, placebo-controlled trial at 127 centres in 15 countries. Patients with HbA(1c) of 7% or greater to 10% or less were eligible for inclusion. Patients with stage 2 CKD (estimated glomerular filtration rate [eGFR] >= 60 to = 30 to